Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer

• Main Authors: Liyun Zheng (Author), Shiji Fang (Author), Aifang Chen (Author), Weiqian Chen (Author), Enqi Qiao (Author), Minjiang Chen (Author), Gaofeng Shu (Author), Dengke Zhang (Author), Chunli Kong (Author), Qiaoyou Weng (Author), Suqin Xu (Author), Zhongwei Zhao (Author), Jiansong Ji (Author)
• Format: Book
• Published: Elsevier, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sorafenib, a multikinase inhibitor, is the first-line agent for advanced liver cancer. Sorafenib strongly inhibits both cell proliferation and tumour angiogenesis. However, the development of drug resistance hampers its anticancer efficacy. To improve the antitumour activity of sorafenib, we demonst...